The Role of Neurologist in the Assessment and Treatment of Depression

BAYAM, Fatma Ece; Kumral, Emre

doi:10.4274/tnd.galenos.2019.44341

The Role of Neurologist in the Assessment and Treatment of Depression

Emre KUMRAL, (Ege Üniversitesi)

Fatma Ece BAYAM (Üsküdar Üniversitesi)

Türk Nöroloji Dergisi

2 0

Yıl: 2020 Cilt: 26 Sayı: 1 Sayfa Aralığı: 1 - 9 Metin Dili: İngilizce DOI: 10.4274/tnd.galenos.2019.44341 İndeks Tarihi: 02-05-2020

The Role of Neurologist in the Assessment and Treatment of Depression

Öz:

In neurologic illness, depression contributes significantly to impairments in quality of life, independent of the severity of the disease. In the evolution ofneurodegenerative disorders, depression may predate neurologic signs and symptoms, and there is some evidence that depressive illness itself may be a risk factor insome dementias. Data on the treatment of depression in neurologic disease are scarce, and often the treatment advice is based on the personal views of psychiatrists.In some patients, diagnosis of depression in neurologic diseases can be particularly hard because of communication difficulties and disturbances of emotionalexpression as a result of neurologic disorders. However, effective screening and diagnostic tools have been developed for the recognition of depression in neurologicdisorders. In recent years, there have been large quantities of clinical trials that supported the critical role of the neurologist in assessing and treating depressivesymptoms to the point of remission. The intention of this review was to demonstrate the importance and role of a neurologist in the diagnosis and treatment ofdepression in neuropsychiatric diseases.

Anahtar Kelime:

Konular: Nörolojik Bilimler

Depresyonun Tanısı ve Sağaltımında Nöroloğun Yeri

Öz:

Nörolojik hastalıklarla beraber görülen depresyon, nörolojik hastalığın ciddiyetinden bağımsız olarak yaşam kalitesindeki bozulmalara önemli ölçüde katkıda bulunur. Nörodejeneratif hastalıkların seyrinde, depresyon nörolojik belirti ve semptomları ortaya çıkarabilir ve bazı bunamalarda depresif hastalığın kendisinin bir risk faktörü olabileceğine dair bazı kanıtlar vardır. Nörolojik hastalıklarda depresyon sağaltımı için kanıtlar sınırlıdır ve genellikle tedavi önerisi psikiyatristlerin kararına dayanmaktadır. Nörolojik durumlarda depresyonun teşhisi, iletişim güçlüğü ve altta yatan nörolojik hastalığın bir sonucu olarak duygusal ifadedeki değişiklikler nedeniyle özellikle zor olabilir. Bununla birlikte, nörolojik bozukluklarda depresyonun tanınması için etkili tarama ve tanılama yöntemleri geliştirilmiştir. Son yıllarda, depresif rahatsızlıkların tanınması ve sağaltımı konusundaki nöroloğun kritik rolünü destekleyen çok sayıda klinik çalışma yapılmıştır. Bu derleme, nöropsikiyatrik hastalıklarda depresyonun tanısında ve sağaltımında bir nöroloğun önemini ve rolünü göstermeyi amaçlamaktadır.

Anahtar Kelime:

Konular: Nörolojik Bilimler

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Veazey C, Aki SOE, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2005;17:310-323.
2. Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Mov Disord 2000;15:1221-1224.
3. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 2004;46:227-232.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed). Arlington, VA: American Psychiatric Publishing, 2013.
5. Moran PJ, Mohr DC. The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med 2005;28:35-41.
6. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 2004;61:162-167.
7. Starkstein SE, Cohen BS, Fedoroff P, Parikh RM, Price TR, Robinson RG. Relationship between anxiety disorders and depressive disorders in patients with cerebrovascular injury. Arch Gen Psychiatry 1990;47:246-251.
8. Jorgensen L, Engstad T, Jacobsen BK. Higher incidence of falls in long-term stroke survivors than in population controls: depressive symptoms predict falls after stroke. Stroke 2002;33:542-547.
9. Pohjasvaara T, Vataja R, Leppavuori A, Kaste M, Erkinjuntti T. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol 2001;8:315-319.
10. Laska AC, Martensson B, Kahan T, von Arbin M, Murray V. Recognition of depression in aphasic stroke Patients. Cerebrovasc Dis 2007;24:74-79.
11. Vataja R, Leppavuori A, Pohjasvaara T, et al. Poststroke depression and lesion location revisited. J Neuropsychiatry Clin Neurosci 2004;16:156- 162.
12. Verdelho A, Henon H, Lebert F, Pasquier F, Leys D. Depressive symptoms after stroke and relationship with dementia: A three-year follow-up study. Neurology 2004;62:905-911.
13. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005;36:1098- 1103.
14. Andersen G, Vestergaard K, Riis J, Lauritzen L. Incidence of poststroke depression during the first year in a large unselected stroke population determined using a valid standardized rating scale. Acta Psychiatr Scand 1994;90:190-195.
15. House A, Dennis M, Mogridge L, Warlow C, Hawton K, Jones L. Mood disorders in the year after first stroke. Br J Psychiatry 1991;158:83-92.
16. Charney DS, Reynolds CF, Lewis L, et al. Depression and Bipolar Support Alliance. Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 2003;60:664-672.
17. Spalletta G, Guida G, De Angelis D, Caltagirone C. Predictors of cognitive level and depression severity are different in patients with left and right hemispheric stroke within the first year of illness. J Neurol 2002;249:1541- 1551.
18. King RB, Shade-Zeldow Y, Carlson CE, Feldman JL, Philip M. Adaptation to stroke: a longitudinal study of depressive symptoms, physical health, and coping process. Top Stroke Rehabil 2002;9:46-66.
19. Desmond DW, Remien RH, Moroney JT, Stern Y, Sano M, Williams JB. Ischemic stroke and depression. J Int Neuropsychol Soc 2003;9:429-439.
20. Ng KC, Chan KL, Straughan PT. A study of post-stroke depression in a rehabilitative center. Acta Psychiatr Scand 1995;92:75-79.
21. Löfgren B, Gustafson Y, Nyberg L. Psychological well-being 3 years after severe stroke. Stroke 1999;30:567-572.
22. Verdelho A, Henon H, Lebert F, Pasquier F, Leys D. Depressive symptoms after stroke and relationship with dementia: a three-year follow-up study. Neurology 2004;62:905-911.
23. Engedal K, Barca ML, Laks J, Selbaek G. Depression in Alzheimer’s disease: specificity of depressive symptoms using three different clinical criteria. Int J Geriatr Psychiatry 2011;26:944-951.
24. Enache D, Winblad B, Aarsland D. Depression in dementia: epidemiology, mechanisms, and treatment. Curr Opin Psychiatry 2011;24:461-472.
25. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008;23:183-189.
26. Royall DR, Palmer R, Chiodo LK, Polk MJ. Depressive symptoms predict longitudinal change in executive control but not memory. Int J Geriatr Psychiatry 2012;27:89-96.
27. Pellegrino LD, Peters ME, Lyketsos CG, Marano CM. Depression in cognitive impairment. Curr Psychiatry Rep 2013;15:384.
28. Sobin C, Sacheim HA. Psychomotor symptoms of depression. Am J Psychiatry 1997;154:4-17.
29. Reichman WE, Coyne AC. Depressive symptoms in Alzheimer’s disease and multi-infarct dementia. J Geriatr Psychiatry Neurol 1995;8:96-99.
30. Boyle LL, Porsteinsson AP, Cui X, King DA, Lyness JM. Depression predicts cognitive disorders in older primary care patients. J Clin Psychiatry 2010;71:74-79.
31. Unützer J. Clinical practice. Late-life depression. N Engl J Med 2007;357:2269-2276.
32. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 2011;10:819-828.
33. Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378:403-411.
34. Goveas SJ, Hogan PE, Kotchen JM, et al. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women’s Health Initiative Memory Study. Int psychogeriatr 2012;24:1252-1264.
35. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 2009;24:2175-2186.
36. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
37. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008;23:183-189.
38. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001;13:187-196.
39. Global Parkinson’s Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002;17:60-67.
40. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol Scand 2006;113:211-220.
41. Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease - epidemiology, mechanisms, and management. Nat Rev Neurol 2012;8:35-47.
42. Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD. Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med 1988;18:49-55.
43. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson’s disease: a multi-centre study with 4 years followup. Brain 2005;128:2240-2249.
44. Global Parkinson’s Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 2002;17:60-67.
45. van der Hoek TC, Bus BA, Matui P, van der Marck MA, Esselink RA, Tendolkar I. Prevalence of depression in Parkinson’s disease: effects of disease stage, motor subtype and gender. J Neurol Sci 2011;310:220-224.
46. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson’s disease: clinical correlates and outcome. Parkinsonism Relat Disord 2003;10:23-28.
47. Menza M, Dobkin RD, Marin H, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson’s disease. Mov Disord 2009;24:1325-1332.
48. Ravina B, Elm J, Camicioli R, et al. The course of depressive symptoms in early Parkinson’s disease. Mov Disord 2009;24:1306-1311.
49. Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry 2011;82:914- 923.
50. van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M. Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord 2013;28:605-611.
51. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.
52. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Antidepressive treatment in Parkinson’s disease A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-DOPA. Acta Neurol Scand 1980;62:210-219.
53. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886- 892.
54. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):42-80.
55. Butler MA, Bennett TL. In search of a conceptualization of multiple sclerosis: a historical perspective. Neuropsychol Rev 2003;13:93-112.
56. Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry 2004;49:157-163.
57. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci 2002;205:51-58.
58. Smith SJ, Young CA. The role of affect on the perception of disability in multiple sclerosis. Clin Rehabil 2000;14:50-54.
59. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002;125:1428-1449.
60. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69:942-949.
61. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990;147:1493-1497.
62. Patten SB, Metz LM; SPECTRIMS Study Group. Interferon beta1a and depression in secondary progressive MS: Data from the SPECTRIMS Trial. Neurology 2002;69:744-746.
63. Hickie IB, Wilson AJ, Wright JM, Bennett BK, Wakefield D, Lloyd AR. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J Clin Psychiatry 2000;61:643-648.
64. Patten SB, Metz LM. Interferon beta-1 a and depression in relapsingremitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001;7:243-248.
65. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012;380:1180-1192.
66. Temkin O. The falling sickness. Baltimore: The Johns Hopkins University Press, 1994.
67. Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012;72:184-191.
68. Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol 2012;11:1093- 1102.
69. Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012;72:184-191.
70. Kanner AM, Ettinger AB. Anxiety disorders. In: Engel J Jr, Pedley TA, editors. Epilepsy: a Comprehensive Textbook. 2nd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2008:2139-2154.
71. 71 Devinsky O, Vazquez B. Behavioral changes associated with epilepsy. Neurol Clin 1993;11:127-149.
72. Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48:2336-2344.
73. Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk? Epilepsia 2009;50:1933-1942.
74. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007;6:693-698.
75. Dikmen S, Bombadier CH, Machamer JE, Fann JR, Temkin NR. Natural history of depression in traumatic brain injury. Arch Phys Med Rehabil 2004;85:1457-1464.
76. Moldover JE, Goldberg KB, Prout MF. Depression after traumatic brain injury: a review of evidence for clinical heterogeneity. Neuropsychol Rev 2004;14:143-154.
77. Jorge RE, Robinson RG, Moser D, Tateno A, Crespo-Facorro B, Arndt S. Major depression following traumatic brain injury. Arch Gen Psychiatry 2004;61:42-50.
78. Levin HS, McCauley SR, Josic CP, et al. Predicting depression following mild traumatic brain injury. Arch Gen Psychiatry 2005;62:523-528.
79. Rowland SM, Lam CS, Leahy B. Use of the Beck Depression InventoryII (BDI-II) with persons with traumatic brain injury. Analysis of factorial structure. Brain Inj 2005;19:77-83.
80. Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil 2005;20:377-388.
81. Benabid AL, Benazzouz A, Hoffmann D, Limousin P, Krack P, Pollak P. Long term electrical inhibition of deep brain targets in movement disorders. Mov Disord 1998;13(Suppl 3):119-125.
82. Fitzgerald PB, Segrave RA. Deep brain stimulation in mental health: Review of evidence for clinical efficacy. Aust N Z J Psychiatry 2015;49:979-993.
83. Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul 2016;9:336-346.
84. Bejjani BP, Damier P, Arnulf I, et al. Transient acute depression by highfrequency deep-brain stimulation. N Engl J Med 1999;340:1476-1480.

APA	Kumral E, BAYAM F (2020). The Role of Neurologist in the Assessment and Treatment of Depression. , 1 - 9. 10.4274/tnd.galenos.2019.44341
Chicago	Kumral Emre,BAYAM Fatma Ece The Role of Neurologist in the Assessment and Treatment of Depression. (2020): 1 - 9. 10.4274/tnd.galenos.2019.44341
MLA	Kumral Emre,BAYAM Fatma Ece The Role of Neurologist in the Assessment and Treatment of Depression. , 2020, ss.1 - 9. 10.4274/tnd.galenos.2019.44341
AMA	Kumral E,BAYAM F The Role of Neurologist in the Assessment and Treatment of Depression. . 2020; 1 - 9. 10.4274/tnd.galenos.2019.44341
Vancouver	Kumral E,BAYAM F The Role of Neurologist in the Assessment and Treatment of Depression. . 2020; 1 - 9. 10.4274/tnd.galenos.2019.44341
IEEE	Kumral E,BAYAM F "The Role of Neurologist in the Assessment and Treatment of Depression." , ss.1 - 9, 2020. 10.4274/tnd.galenos.2019.44341
ISNAD	Kumral, Emre - BAYAM, Fatma Ece. "The Role of Neurologist in the Assessment and Treatment of Depression". (2020), 1-9. https://doi.org/10.4274/tnd.galenos.2019.44341

APA	Kumral E, BAYAM F (2020). The Role of Neurologist in the Assessment and Treatment of Depression. Türk Nöroloji Dergisi, 26(1), 1 - 9. 10.4274/tnd.galenos.2019.44341
Chicago	Kumral Emre,BAYAM Fatma Ece The Role of Neurologist in the Assessment and Treatment of Depression. Türk Nöroloji Dergisi 26, no.1 (2020): 1 - 9. 10.4274/tnd.galenos.2019.44341
MLA	Kumral Emre,BAYAM Fatma Ece The Role of Neurologist in the Assessment and Treatment of Depression. Türk Nöroloji Dergisi, vol.26, no.1, 2020, ss.1 - 9. 10.4274/tnd.galenos.2019.44341
AMA	Kumral E,BAYAM F The Role of Neurologist in the Assessment and Treatment of Depression. Türk Nöroloji Dergisi. 2020; 26(1): 1 - 9. 10.4274/tnd.galenos.2019.44341
Vancouver	Kumral E,BAYAM F The Role of Neurologist in the Assessment and Treatment of Depression. Türk Nöroloji Dergisi. 2020; 26(1): 1 - 9. 10.4274/tnd.galenos.2019.44341
IEEE	Kumral E,BAYAM F "The Role of Neurologist in the Assessment and Treatment of Depression." Türk Nöroloji Dergisi, 26, ss.1 - 9, 2020. 10.4274/tnd.galenos.2019.44341
ISNAD	Kumral, Emre - BAYAM, Fatma Ece. "The Role of Neurologist in the Assessment and Treatment of Depression". Türk Nöroloji Dergisi 26/1 (2020), 1-9. https://doi.org/10.4274/tnd.galenos.2019.44341